HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists <it>in vitro </it>has an inherent, low-level ability to utilize MVC-bound CCR5 for entry

by Westby Mike, Jubb Becky, Salimiseyedabad Hamid, Ellett Anne, Jakobsen Martin R, Roche Michael, Lee Benhur, Lewin Sharon R, Churchill Melissa J, Gorry Paul R
Published 2011-11-01